Article Text

Download PDFPDF
Topical tacrolimus treatment in a patient with dermatomyositis
  1. C E Lampropoulos,
  2. D P D’ Cruz
  1. Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK
  1. Correspondence to:
    Dr D P D’ Cruz
    The Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, 4, Lambeth Palace Road, London SE1 7EH, UK; david.d'cruzkcl.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dermatomyositis is an idiopathic inflammatory process manifested by proximal muscle weakness and cutaneous lesions such as Gottron’s sign, heliotrope rash, erythematous photosensitive rash, or periungual erythema. Other unusual cutaneous manifestations are icthyosis, panniculitis, erythroderma, lichen planus, vesicle and bullae formation, follicular hyperkeratosis, malacoplakia, and papular mucinosis.1 Administration of systemic agents such as corticosteroids, methotrexate (MTX), hydroxychloroquine (HCQ), mycophenolate mofetil, intravenous immunoglobulins, and/or azathioprine for the underlying systemic disease leads in many cases to remission of the cutaneous lesions. Nevertheless, many patients have resistant cutaneous lesions despite treatment. On the other hand, cutaneous lesions may be the major manifestation of the disease, making it difficult to justify systemic agents because of their side effects.

CASE REPORT

A 61 year old woman with dermatomyositis and cutaneous lesions, refractory to previous treatment, …

View Full Text

Footnotes

  • Competing interest statement: Neither of the authors have any competing interests.